IL163067A - Isolated heterodimeric cytokine receptor - Google Patents

Isolated heterodimeric cytokine receptor

Info

Publication number
IL163067A
IL163067A IL163067A IL16306704A IL163067A IL 163067 A IL163067 A IL 163067A IL 163067 A IL163067 A IL 163067A IL 16306704 A IL16306704 A IL 16306704A IL 163067 A IL163067 A IL 163067A
Authority
IL
Israel
Prior art keywords
cytokine receptor
methods
heterodimeric cytokine
multimeric
isolated heterodimeric
Prior art date
Application number
IL163067A
Other languages
English (en)
Hebrew (he)
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of IL163067A publication Critical patent/IL163067A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL163067A 2002-01-18 2004-07-15 Isolated heterodimeric cytokine receptor IL163067A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35032502P 2002-01-18 2002-01-18
US38910802P 2002-06-14 2002-06-14
US43536102P 2002-12-19 2002-12-19
PCT/US2003/001983 WO2004003140A2 (en) 2002-01-18 2003-01-21 Cytokine receptor zcytor17 multimers

Publications (1)

Publication Number Publication Date
IL163067A true IL163067A (en) 2013-07-31

Family

ID=30003762

Family Applications (3)

Application Number Title Priority Date Filing Date
IL226637A IL226637A (en) 2002-01-18 2004-07-15 Isolated heterodimeric cytokine receptor
IL163067A IL163067A (en) 2002-01-18 2004-07-15 Isolated heterodimeric cytokine receptor
IL226637A IL226637A0 (en) 2002-01-18 2013-05-29 An isolated heterodimeric cytokine receptor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL226637A IL226637A (en) 2002-01-18 2004-07-15 Isolated heterodimeric cytokine receptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL226637A IL226637A0 (en) 2002-01-18 2013-05-29 An isolated heterodimeric cytokine receptor

Country Status (13)

Country Link
US (24) US7494804B2 (OSRAM)
EP (3) EP2338910B1 (OSRAM)
JP (2) JP4511349B2 (OSRAM)
AT (1) ATE547430T1 (OSRAM)
AU (1) AU2003280410B8 (OSRAM)
CA (1) CA2473733C (OSRAM)
CY (1) CY1112787T1 (OSRAM)
DK (1) DK1576112T3 (OSRAM)
ES (2) ES2546797T3 (OSRAM)
IL (3) IL226637A (OSRAM)
PT (1) PT1576112E (OSRAM)
SI (1) SI1576112T1 (OSRAM)
WO (1) WO2004003140A2 (OSRAM)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455852T1 (de) 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
AU7445900A (en) 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
SI2230299T1 (sl) 2002-01-18 2012-07-31 Zymogenetics Inc Nov citokinski zcytor ligand
US7494804B2 (en) * 2002-01-18 2009-02-24 Zymogenetics, Inc. Polynucleotide encoding cytokine receptor zcytor17 multimer
US9738700B2 (en) 2002-01-18 2017-08-22 Zymogenetics Inc. ZCYTOR17 heterodimeric cytokine receptor
JP2007068402A (ja) * 2003-12-26 2007-03-22 Bml Inc 免疫応答調節蛋白質
US20060269991A1 (en) * 2004-11-03 2006-11-30 Boehringer Ingelheim Pharmaceuticals, Inc. T cell protein and nucleotides encoding the same
CA2594502A1 (en) * 2005-01-28 2006-08-03 Zymogenetics Inc. Homogeneous preparations of il-31
CA2594490A1 (en) 2005-02-14 2006-08-24 Zymogenetics Inc. Methods of treating skin disorders using an il-31ra antagonist
AU2012202218B2 (en) * 2005-02-14 2014-05-22 National Jewish Medical And Research Center Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
AU2006214325B2 (en) * 2005-02-14 2012-04-05 National Jewish Medical And Research Center Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
JP5065253B2 (ja) * 2005-05-06 2012-10-31 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１モノクローナル抗体とその使用法
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
US7972776B2 (en) 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
JP2009528264A (ja) 2006-01-10 2009-08-06 ザイモジェネティクス，インコーポレイティド Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法
CA2647846C (en) * 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CA2654623C (en) * 2006-06-08 2016-07-26 Chugai Seiyaku Kabushiki Kaisha An anti-nr10/il-31ra antibody for use in preventing or treating an inflammatory disease
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
US20100093076A1 (en) * 2006-08-25 2010-04-15 Moore Margaret D Soluble il-27 receptor
PL2594586T3 (pl) * 2006-09-01 2015-02-27 Zymogenetics Inc Przeciwciała monoklonalne IL-31 i sposoby ich zastosowania
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8865162B2 (en) 2008-06-13 2014-10-21 Oncohealth Corp. Monoclonal antibodies against HPV proteins
US7799323B2 (en) 2007-01-10 2010-09-21 Zymogenetics, Inc. Methods of using IL-31 to treat airway hyper-responsiveness and asthma
WO2009041613A1 (ja) * 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
MY185647A (en) 2007-12-05 2021-05-27 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
KR20160074019A (ko) * 2007-12-05 2016-06-27 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
CA2708251C (en) 2007-12-07 2016-04-12 Zymogenetics, Inc. Humanized antibody molecules specific for il-31
KR102269708B1 (ko) 2008-04-11 2021-06-25 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
EP4231014A3 (en) 2010-11-30 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
RS60050B1 (sr) 2011-01-18 2020-04-30 Bioniz Llc Kompozicije za modulaciju aktivnosti gama-c-citokina
EP3456743B1 (en) 2013-05-30 2021-08-18 Kiniksa Pharmaceuticals, Ltd. Oncostatin m receptor antigen binding proteins
US10464982B2 (en) 2014-04-23 2019-11-05 Emory University Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto
HRP20250972T1 (hr) 2015-04-14 2025-10-10 Chugai Seiyaku Kabushiki Kaisha Farmaceutski pripravak za prevenciju i/ili liječenje atopijskog dermatitisa koji sadrži il-31 antagonist kao djelatni sastojak
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
CN108135504B (zh) 2015-09-23 2021-08-24 皇家飞利浦有限公司 具有可互换模块的模块化监控设备平台
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10322165B2 (en) * 2017-07-26 2019-06-18 Academia Sinica TIFA antagonists and their use for treating diseases
CR20200099A (es) 2017-08-03 2020-07-24 Amgen Inc Muteínas de interleucina 21 y métodos de tratamiento
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
WO2020227019A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
EP4062933A4 (en) 2019-11-20 2023-12-13 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
AU2021297801A1 (en) * 2020-06-24 2023-02-02 Bioniz Therapeutics, Inc. Antagonistic peptide targeting IL-2, IL-9, and IL-15 signaling for the treatment of cytokine-release syndrome and cytokine storm associated disorders
WO2022049614A1 (ja) 2020-09-01 2022-03-10 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4615974A (en) 1981-08-25 1986-10-07 Celltech Limited Yeast expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
CA1280080C (en) 1984-12-06 1991-02-12 Jacques Oberto Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
JPH06504438A (ja) 1990-12-13 1994-05-26 イミュネックス・コーポレーション 白血病抑制因子受容体
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
CA2144651A1 (en) 1992-09-14 1994-03-31 Timothy J. Miller Immortalized cells and uses therefor
US5906928A (en) 1993-07-30 1999-05-25 University Of Medicine And Dentistry Of New Jersey Efficient gene transfer into primary murine lymphocytes obviating the need for drug selection
EP0745132A1 (en) 1994-02-14 1996-12-04 ZymoGenetics, Inc. Method for preparing orphan receptor ligands
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
CN1075387C (zh) * 1994-12-29 2001-11-28 中外制药株式会社 含有il－6拮抗剂的抗肿瘤剂的作用增强剂
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
CA2237039A1 (en) 1995-11-09 1997-05-15 Zymogenetics, Inc. Production of gad65 in methylotrophic yeast
US5792850A (en) * 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
WO1998002565A1 (en) 1996-07-17 1998-01-22 Zymogenetics, Inc. TRANSFORMATION OF $i(PICHIA METHANOLICA)
JP2002514049A (ja) 1996-07-17 2002-05-14 ザイモジェネティクス，インコーポレイティド ピヒア・メタノリカの栄養要求性突然変異体の製造
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
GB9819420D0 (en) 1998-09-07 1998-10-28 Glaxo Group Ltd Novel receptor
DE60041697D1 (de) 1999-06-01 2009-04-16 Schering Corp Säugetier-rezeptorproteine; ähnliche reagentien und methoden
ATE455852T1 (de) * 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
KR100840033B1 (ko) * 1999-10-20 2008-06-19 제넨테크, 인크. Ｔ 헬퍼 세포 매개 질환의 치료를 위한 ｔ 세포 분화의 조절
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2412211A1 (en) 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2412239C (en) * 2000-06-26 2013-05-28 Zymogenetics, Inc. Cytokine receptor zcytor17
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
AU2002223182B2 (en) * 2000-10-06 2007-08-30 Immunex Corporation Hematopoietin receptors HPR1 and HPR2
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
SI2230299T1 (sl) * 2002-01-18 2012-07-31 Zymogenetics Inc Nov citokinski zcytor ligand
US7494804B2 (en) 2002-01-18 2009-02-24 Zymogenetics, Inc. Polynucleotide encoding cytokine receptor zcytor17 multimer
WO2003072740A2 (en) * 2002-02-25 2003-09-04 Genentech, Inc. Novel type-1 cytokine receptor glm-r
US7552497B2 (en) * 2002-03-26 2009-06-30 Colgate-Palmolive Company Powered toothbrush with rotating sections
CA2594490A1 (en) * 2005-02-14 2006-08-24 Zymogenetics Inc. Methods of treating skin disorders using an il-31ra antagonist

Also Published As

Publication number Publication date
EP2840089A1 (en) 2015-02-25
US8647866B2 (en) 2014-02-11
US20110318354A1 (en) 2011-12-29
US20100266499A1 (en) 2010-10-21
JP4511349B2 (ja) 2010-07-28
ES2546797T3 (es) 2015-09-28
IL226637A0 (en) 2013-06-27
US20070140963A1 (en) 2007-06-21
WO2004003140A2 (en) 2004-01-08
CA2473733A1 (en) 2004-01-08
EP2338910A1 (en) 2011-06-29
US20100055101A1 (en) 2010-03-04
US20030215838A1 (en) 2003-11-20
US20070048835A1 (en) 2007-03-01
CY1112787T1 (el) 2016-02-10
US20100266597A1 (en) 2010-10-21
US20140141485A1 (en) 2014-05-22
US20090274694A1 (en) 2009-11-05
AU2003280410B8 (en) 2009-04-23
US20170320931A1 (en) 2017-11-09
EP1576112B1 (en) 2012-02-29
EP1576112A4 (en) 2007-09-05
US20070048222A1 (en) 2007-03-01
US20160002340A1 (en) 2016-01-07
US20130143265A1 (en) 2013-06-06
US20070048223A1 (en) 2007-03-01
JP2010043120A (ja) 2010-02-25
US20180346584A1 (en) 2018-12-06
US7494804B2 (en) 2009-02-24
JP2006500919A (ja) 2006-01-12
AU2003280410A1 (en) 2004-01-19
CA2473733C (en) 2014-09-09
EP2338910B1 (en) 2015-07-08
US20070048832A1 (en) 2007-03-01
ATE547430T1 (de) 2012-03-15
DK1576112T3 (da) 2012-06-25
US20070048831A1 (en) 2007-03-01
US20070048833A1 (en) 2007-03-01
US20170369580A1 (en) 2017-12-28
AU2003280410B2 (en) 2009-04-02
PT1576112E (pt) 2012-05-25
US20070140964A1 (en) 2007-06-21
ES2382800T3 (es) 2012-06-13
US10227415B2 (en) 2019-03-12
US9212213B2 (en) 2015-12-15
US20070049530A1 (en) 2007-03-01
IL226637A (en) 2017-11-30
US20070048834A1 (en) 2007-03-01
SI1576112T1 (sl) 2012-10-30
WO2004003140A3 (en) 2005-09-01
EP1576112A2 (en) 2005-09-21
US20170204190A1 (en) 2017-07-20
US20120264168A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
IL163067A (en) Isolated heterodimeric cytokine receptor
AU2001253127A1 (en) Soluble zalpha11 cytokine receptors
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
SG149693A1 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
IL173559A0 (en) Nogo receptor antagonists
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
DE69738066D1 (de) Hematopoietischer zytokin rezeptor
DK0931092T3 (da) Varianter af vækstfaktor for vaskulære endotelceller med antagonistiske egenskaber
WO2000053761A3 (en) Human cytokine as ligand of the zalpha receptor and uses thereof
WO2002000721A3 (en) Cytokine receptor zcytor17
AU3988401A (en) Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
DE60140213D1 (de) Zytokine rezeptor zcytor19
ZA200508390B (en) Compositions and methods for the therapy of inflammatory bowel disease
CA2530027A1 (en) Novel melanocortin receptor templates, peptides, and use thereof
EP1660517A4 (en) ANTAGONISTS OF NOGO RECEPTOR
NZ510744A (en) Cytokine receptor zalpha11
WO2003002604A3 (en) G protein coupled receptors and dna sequences thereof
WO2003018798A3 (en) G-protein coupled receptor and dna sequences thereof
UA87122C2 (ru) Агонисты рецепторов глюкагонподобного пептида-1, их применение и способ получения
WO2002102839A3 (en) Novel g-protein coupled receptors and dna sequences thereof
ATE339447T1 (de) Hochaffine antagonisten der elr-cxc chemokine
EP1736545A3 (en) Soluble zcytor 11 cytokine receptors
Dower et al. MDK-271: A dual function molecule consisting of empirically-designed peptidyl agonists of IL-2/15Rβγc and IL-7Rαγc, unrelated to IL-2, IL-15, or IL-7, incorporated into a bispecific Fc fusion protein
MY143213A (en) Ifnar2 mutants, their production and use
UA84540C2 (en) Novel cytokine zcytor17 ligand

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees